Fosun Pharmaceutical (02196) Affiliated Mycogen Health was approved for clinical trials by the US FDA

Zhitongcaijing · 6d ago

According to Zhitong Finance App, Fosun Pharmaceutical (02196) announced that the company's holding subsidiary Shanghai Juji Health Technology Co., Ltd. (hereinafter referred to as “Mycoji Health”) has received approval from the US FDA (the US Food and Drug Administration) to allow LBP-Shc4 to conduct clinical trials. Mycohealth plans to conduct phase I clinical trials of LBP-Shc4 when conditions are met.

LBP-shc4 is a live biotherapeutic product independently developed by the Group and intended for the treatment of androgenic alopecia (AGA).

As of April 2025, the Group's cumulative R&D investment for LBP-Shc4 at this stage is approximately RMB 0.17 billion (unaudited).